WIGDAN AHMED MEDANI

• Identified health conditions through targeted physical examinations.
• Ordered and interpreted investigations, utilizing exceptional communication skills to provide relevant findings to patients.
• Safely prescribed and administered medications including analgesia, intravenous fluids
• Presented cases at clinical meetings facilitating collective learning and knowledge sharing.
• Assisted in emergency situations and complex surgical procedures for improved patient outcomes.
• Performed diligent surgical care tasks including pre-operative evaluation, operative management and post-operative care.
• Delivered targeted follow-up care for continued patient monitoring.
• Rotated across different specialties gaining a holistic understanding of medical practice.
• Identified health conditions through targeted physical examinations.

• Identified health conditions through targeted physical examinations.
• Assessed diagnostic findings to determine patient treatment plans.
• Prescribed medication to treat diagnosed conditions or illnesses.
• Ensured continuous care with regular follow-up appointments.
• Generated referrals for patients in need of specialized care and completed paperwork to facilitate seamless transfers.

• Internal medicine and Cardiology department
• Observed and assisted in patient consultations, history taking, and clinical examinations.
• Attended ward rounds, outpatient clinics, and case discussions on complex medical and cardiac cases.
• Gained exposure to ECG interpretation, echocardiograms, and cardiology procedures.
• Participated in medical documentation, discharge summaries, and multidisciplinary team discussions.
• Engaged in academic activities, including clinical teaching sessions and case presentations

General Practitioner

Sheikh Khalifa Medical City (SKMC) – Internal Medicine Department April 2020 – July 2020

• Provided frontline medical care to COVID-19 patients in internal medicine wards and emergency department.
• Managed acute respiratory cases, monitored vital signs, and assisted in patient stabilization.
• Coordinated with multidisciplinary teams to implement COVID-19 treatment protocols.

ADNEC – Sinopharm COVID-19 Vaccine Trial
July 2020 – January 2021

• Served as a sub investigator in the Sinopharm Phase III Vaccine Trial at the Abu Dhabi National Exhibition Centre (ADNEC).
• Conducted patient screening, enrollment, follow-ups, and monitored post-vaccination adverse effects.
• data management and audit processes to ensure compliance with research protocols

Sheikh Khalifa Medical City (SKMC) – Internal Medicine (COVID-19 Unit)
January 2021 – December 2021

• Managed COVID-19 patients in both inpatient and HDU settings.
• Oversaw treatment regimens, oxygen therapy, and complications management.
• Contributed to clinical decision-making and research discussions regarding emerging COVID-19 therapies.

Al Rahba Hospital | SKMC Diabetic Center | ADHRC
December 2021 – Present

Actively involved in multiple research studies, as sub investigator:

Research as sub-investigator

1. Inactivated SARS CoV 2Vaccines (Vero Cell)Clinical Trial.

2. Immunogenicity, Non inferiority Immuno-bridging Study of InactivatedSARS CoV 2 Vaccine in healthy population aged 3-17 years old VS healthy population aged18 years old and above .

3. Sequential Immunization of Recombinant COVID 19 vaccine (CHOcells) and Inactivated COVID 19 Vaccine (Verocells) in Population Aged 18 Years and above.

4. Safety and immunogenicity of a broad spectrum mosaic vaccine as a booster dose against SARS -CoV-2 Omicron and other circulating variants.

5. Safety and immunogenicity of a hybrid -type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.

6.Effectiveness of BBIBP- CorV vaccine against severe outcomes of COVID -19 in Abu Dhabi, United Arab Emirates.

7. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CoV: phase 2 trial.

8. The incidence of COVID-19 infection following emergency use authorization of BBIBP- CORV in activated vaccine in frontline workers in the United Arab Emirates .

9. Safety and immunogenicity of a heterologous boost with a recombinant vaccine,NVSI-06-07, in the inactivated vaccine recipients from UAE: a phase-2 randomized ,double-blinded, controlled clinical trial.

10. Effect of 2 Inactivated SARS CoV 2 Vaccines on Symptomatic COVID 19 Infection in Adults: A Randomized Clinical Trial.

11.A Multicenter low Interventional Clinical Trial of Exponential Deep Examination (EDE) scanner compared to bacterial culture in identifying antimicrobial resistance

12.Study on Clinical Use of EVUSHELD (AZD7442) as Pre exposure Prophylaxis

13.Supernova clinical trial

14.Evaluation of ovarian reserve among Emirati women

15.Drug survival of biologic treatments in the management of Psoriasis

16.Phase 3 study to evaluate the efficacy and safety of amlitelimab in participants with moderate-to-severe atopic dermatitis (AD)

17.An International, Phase 2/3 Study, Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study

18.Predective study

19.Metabolic dysfunction-associated fatty liver disease in Emirati children and adolescents